Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 1100 participants.
Also called NCT01459627
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,100 participants
- Sponsor
- Registry
-
NCT01459627
-
- Other papers using this trial's data
- Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial
- Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands, Norway, Poland, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01459627. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2017-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI
- Acronym
- DAPT-STEMI
- Condition
- Myocardial Infarction
- Condition
- Cardiovascular Disease
- Intervention (Other)
- 6 months DAPT
- Intervention (Other)
- 12 months DAPT
- Lead sponsor
- Maasstad Hospital
- Collaborator
- Medtronic
Record details
- Record id
cardio:ct-nct01459627- Content hash
dfb47241d018196814db66df500816da7daa9a7e19e7ca4347ccad3ec46f44e6